Nature Communications · 2020 · 22 citations · 56 references
MedicineCancer BiologyOncologyCarcinogenesisMolecular OncologyOncogenesCancer ImmunotherapyHematologic Malignancy TherapyAcute Lymphoblastic Leukemia BiologyAcute Lymphoblastic Leukemia TreatmentChemokine Receptor AntagonismInterleukin-7 SignalingKinase InhibitorsOncogenic Fusion MechanismsOncogenic Fusion ProteinsXenotransplantation Models
Abstract Ph + acute lymphoblastic leukemia (ALL) is characterized by the expression of an oncogenic fusion kinase termed BCR-ABL1. Here, we show that interleukin 7 receptor (IL7R) interacts with the chemokine receptor CXCR4 to recruit BCR-ABL1 and JAK kinases in close proximity. Treatment with BCR-ABL1 kinase inhibitors results in elevated expression of IL7R which enables the survival of transformed cells when IL7 was added together with the kinase inhibitors. Importantly, treatment with anti-IL7R antibodies prevents leukemia development in xenotransplantation models using patient-derived Ph + ALL cells. Our results suggest that the association between IL7R and CXCR4 serves as molecular platform for BCR-ABL1-induced transformation and development of Ph + ALL. Targeting this platform with anti-IL7R antibody eliminates Ph + ALL cells including those with resistance to commonly used ABL1 kinase inhibitors. Thus, anti-IL7R antibodies may provide alternative treatment options for ALL in general and may suppress incurable drug-resistant leukemia forms.
56
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text
Medicine, Hematology, Oncology +13
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Neil P. Shah, Chris Tran, Francis Y. Lee et al. · Science · 2004 · 1.8K citations
Medicine, Oncology, Pharmacology +14